CASI Pharmaceuticals to build new manufacturing site in China

CASI Pharmaceuticals to build new manufacturing site in China

November 16, 2018 390

CASI Pharmaceuticals, a biopharmaceutical company, announces that it has entered into framework agreements to build a state-of-the-art manufacturing site strategically located in the Wuxi Huishan Economic Development Zone in Jiangsu Province (China).

The Wuxi Huishan Economic Development Zone is a leading science and technology innovation center in the region.

The facility will be designed and constructed based on global cGMP requirements and is expected to have capacity for large scale production. The plant will be a key asset supporting CASI’s growth and commercialization plans with further agreements to be finalized and site construction to begin in mid-2019.

CASI Pharmaceuticals (Rockville, USA)  is a biopharmaceutical company with a wholly owned subsidiary and R&D operations in Beijing (China). Its product pipeline features three U.S. Food and Drug Administration (FDA)-approved drugs in-licensed from Spectrum Pharmaceuticals. The company also acquired a portfolio of 25 FDA-approved abbreviated new drug applications (ANDAs), and four pipeline ANDAs that are pending FDA approval from Sandoz, and recently acquired an HBV ANDA from Laurus Labs.

 

Information source: https://gmpnews.net/2018/11/casi-pharmaceuticals-to-build-new-manufacturing-site-in-china/

Block ?

If this page is in your subscriptions, then it will be removed. You will not see this page. If you want to unblock a user, go to the settings, the list of blocked users and click unblock

Complain

The user will not know who exactly sent the complaint

Delete Company

The user will not know who exactly sent the complaint

Notifications

You Have 112 readed notifications

CHATS

Select chat category

×